Table 3.

Correlation of SMYD3 VNTR polymorphism with clinic-pathologic characteristics of patients.

Clinical charateristics	2/2+2/3	3/3	OR value (95%CI)	P
Age (age)				0.309
<45	13 (39.4%)	37 (30.1%)	1 (reference)
≥45	20 (60.6%)	86 (69.9%)	0.662 (0.298–1.470)
First menstruation (age)				0.699
<13	16 (48.5%)	55 (44.7%)	1 (reference)
≥13	17 (51.5%)	68 (55.3%)	0.859 (0.398–1.856)
First childbearing age				0.399
<20	15 (45.5%)	46 (37.4%)	1 (reference)
≥20	18 (54.5%)	77 (62.6%)	0.717 (0.329–1.559)
Last childbearing age				0.988
<40	19 (57.6%)	71 (57.7%)	1 (reference)
≥40	14 (42.4%)	52 (42.3%)	1.006 (0.462–2.190)
Mesntruation codition				0.508
Premenopause	24 (72.7%)	82 (66.7%)	1 (reference)
Postmenopause	9 (27.3%)	41 (33.3%)	0.750 (0.319–1.760)
Abortion history				0.333
No	23 (69.7%)	80 (65.0%)	1 (reference)
Yes	10 (30.3%)	43 (35.0%)	1.545 (0.637–3.748)
Tumor classification
HGSC	17 (51.5%)	79 (64.2%)	1 (reference)
EC	4 (12.1%)	13 (10.6%)	1.105 (0.327–3.729)	0.872
CCC	5 (15.2%)	13 (10.6%)	1.381 (0.444–4.296)	0.576
MC	5 (15.2%)	14 (11.4%)	1.282 (0.416–3.952)	0.664
LGSC	2 (6.0%)	4 (3.2%)	1.795 (0.308–10.46)	0.509
Tumor differentiation				0.017
Middle/high differentiation	29 (87.9%)	89 (72.3%)	1 (reference)
Low differentiation	4 (12.1%)	44 (35.7%)	3.584(1.186–10.840)
FIGO staging				0.045
I–II	27 (81.8%)	78 (63.4%)	1 (reference)
III–IV	6 (18.2%)	45 (36.6%)	0.385 (0.148–1.004)

P value was detected by Wilcoxon rank-sum test; OR – odd ratio; CI – confidence interval; EC – endometrial carcinoma; CCC – clear cell carcinoma; MC – mucin-like cell carcinoma; HGSC – high-grade serous adenocarcinoma; LGSC – low-grade serous adenocarcinoma; FIGO – International Federation of Gynecology and Obstetrics.